Recombinant Protein Therapeutics CDMO Market Analysis

Recombinant Protein Therapeutics CDMO Market Analysis

Based on type, the market is segmented into oncology agents, insulins, immunostimulating and immunosuppressive agents, autoimmune, interferons, vaccines, blood coagulation factors, growth hormones, and other types. The oncology agents segment was valued at USD 4.5 billion in 2023.

• The field of oncology has witnessed rapid advancements in biologic therapies, particularly monoclonal antibodies targeting cancer-specific antigens or signaling pathways. These biologics have demonstrated significant clinical efficacy and improved patient outcomes in various types of cancer, thereby increasing the demand for outsourcing services.

   

• As a result, pharmaceutical companies are investing heavily in the development of novel oncology biologics, including recombinant protein therapeutics. Thus, these factors are contributing to a higher market share for the oncology segment in the market.

   

To get key market trends

  Download Free Sample

Based on source, the recombinant protein therapeutics CDMO market is classified into mammalian, E. coli, S. cerevisiae, and other sources. The mammalian segment dominated the market with 61.5% of business share in 2023.
 

• Mammalian cells, particularly Chinese hamster ovary (CHO) cells, are preferred to produce complex protein therapeutics such as cytokines and growth factors. Thus, the diversity and complexity of protein therapeutics produced using mammalian cells contribute to dominance of this segment.
   
• Moreover, protein therapeutics produced in mammalian cells have gained widespread clinical acceptance and regulatory approval, contributing to the highest market share.
   
• Additionally, mammalian cell culture systems offer scalability and manufacturing expertise necessary for large-scale production, further bolstering their adoption in CDMOs and biopharmaceutical companies.
   

Based on therapeutic areas, the recombinant protein therapeutics CDMO market is divided into oncology, metabolic disorders, immunological disorders, infectious diseases, haematological disorders, women health, and other therapeutic areas. The oncology segment is expected to grow at a CAGR of 15.3% from 2024 – 2032.
 

• Cancer is one of the leading causes of morbidity and mortality worldwide, with a continuously increasing prevalence. The rising incidence of various types of cancer, including breast, lung, colorectal, and prostate cancers, drives the demand for oncology therapeutics, including recombinant protein-based drugs.
   
• Additionally, recombinant protein therapeutics, such as monoclonal antibodies and cytokines, offer targeted and personalized treatment options with reduced toxicity compared to conventional chemotherapy, further enhancing the adoption and demand for such therapies.
   
• Thus, as the understanding of cancer biology and treatment modalities advances, there is a growing demand for biologic therapies tailored to specific molecular targets and patient populations, driving the oncology segment share.
   

Based on service type, the recombinant protein therapeutics CDMO market is categorized into contract manufacturing and contract development. The contract manufacturing segment is anticipated to reach USD 43.6 billion by 2032.
 

• The increasing demand for recombinant protein therapeutics such as insulin, interferons, oncology agents among others in pharmaceutical and biotechnology companies significantly drives the growth of contract manufacturing segment.
   
• Additionally, several advantages offered by contract manufacturing services such as scalability, flexibility, cost-effectiveness, state-of-the-art facilities, equipment, and expertise supports the growth of this segment.
   

Based on end-user, the recombinant protein therapeutics CDMO market is segmented into pharmaceutical companies, biotechnology companies, and other end-users. The pharmaceutical companies segment held market share of 50.2% in 2023 and is anticipated to continue dominating the market.
 

• Outsourcing to CDMOs enables pharmaceutical firms to accelerate drug development timelines while focusing on their core competencies, driving demand for CDMO services in the market.
   
• Further, outsourcing manufacturing activities to CDMOs offers cost-effective solutions for pharmaceutical companies by eliminating the need for significant upfront investments in infrastructure, equipment, and personnel.
   

North America recombinant protein therapeutics CDMO market exceeded USD 8.5 billion in 2023 and is anticipated to reach USD 26.7 billion by 2032.
 

• Access to advanced technologies, state-of-the-art infrastructure, and cutting-edge research capabilities solidify North America's position in the market.
   
• CDMOs in the region leverage these resources to provide innovative solutions and high-quality services to their clients.
   
• Additionally, the region boasts a robust ecosystem of pharmaceutical companies, biotechnology startups, academic research institutions coupled with several CDMOs. This favorable ecosystem of industries further aids in the regional market growth.
   
• Thus, with a long history of innovation and investment in biotechnology, North America has emerged as a global leader in biologic drug development and manufacturing, driving significant demand for CDMO services in the region.